{"entity":{"id":"fx-909","kind":"drug","name":"FX-909","aka":[],"tldr":"FX-909 is an experimental pill from Flare Therapeutics, in phase 1 trials for advanced urothelial (bladder) cancer.","summary":"FX-909 is a small molecule, oral from Flare Therapeutics. Blocks PPARG, a transcription factor that the company describes as the master regulator of the luminal lineage of bladder cancer cells. The phase 1 study NCT05929235 tests it alone and with pembrolizumab; the company describes a randomised phase 1b part in PPARG-high locally advanced or metastatic urothelial cancer after earlier treatment. Whether it works in people has not been established.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"Flare Therapeutics FX-909","url":"https://www.flaretx.com/fx-909/"},{"label":"ClinicalTrials.gov NCT05929235","url":"https://clinicaltrials.gov/study/NCT05929235"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":["pparg"],"drugs":[],"companies":["flare-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05929235"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"FX-909","modality":"Small molecule, oral","mechanism":"Blocks PPARG, a transcription factor that the company describes as the master regulator of the luminal lineage of bladder cancer cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/fx-909/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"target":[{"id":"pparg","kind":"target","name":"PPARG","route":"/targets/pparg/"}],"company":[{"id":"flare-therapeutics","kind":"company","name":"Flare Therapeutics","route":"/companies/flare-therapeutics/"}],"trial":[{"id":"nct05929235","kind":"trial","name":"A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma","route":"/trials/nct05929235/"}]}}